Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1311)	8/16/2005 4:52:03 PM
From: Jibacoa	Read Replies (2) \| Respond to of 3722

ANX was aong the few Biotechs that were able to hold their own against the market's downcurrents.<g> ANX has continued to report higher losses in the first 2Qs but they reportedly still have around $0.20/shr in cash with no significant LTD and Carl Icahn now holds more than 12% of the shares after buying 4.3M and 4.3M of warrants on July 27 in a private placement in which he paid more than $8M. The company has been having some good news lately.<g> On June 20 it announced the results of its PII on 50 patients with colon Ca that were treated with its CoFactor and 5-FU and 65% showed tumor response or stable disease after therapy and in general, the treatment was well tolerated. On July 5 it was added to Russells Microcap list, and on July 22 it announced that in vitro studies showed that Thiovir was effective against HIV-1 The stock was up more than 7% and it seems that it wants to resume its previous uptrend.<g> bigcharts.marketwatch.com Bernard